The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC).
 
Rui Wang
No Relationships to Disclose
 
Jasmeet Chadha Singh
No Relationships to Disclose
 
Serena Tsan-Lai Wong
No Relationships to Disclose
 
Diana Lake
Consulting or Advisory Role - Genentech
 
Neil M. Iyengar
Consulting or Advisory Role - Novartis; Seagen
Research Funding - American Cancer Society (Inst); Breast Cancer Research Foundation (Inst); Conquer Cancer Foundation (Inst); National Cancer Institute (Inst); Novartis (Inst)
 
Gabriella D'Andrea
Leadership - ClearView Healthcare Partners; Gerson Lehrman Group; Guidepoint Global; Guidepoint Global; IPG; Third Bridge
Stock and Other Ownership Interests - Abbvie; Abbvie; Johnson & Johnson/Janssen; Medtronic; pfizer; viatris
Expert Testimony - Our Lady of Bellefonte Hospital; University of Maryland
 
Julia P. Brockway-Marchello
No Relationships to Disclose
 
Asta Kaba
No Relationships to Disclose
 
Tiffany A. Traina
Consulting or Advisory Role - Aduro Biotech; Advaxis; AstraZeneca; Athenex; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genomic Health; Halozyme; Immunomedics; Innocrin Pharma; Ionis Pharmaceuticals; Merck; Pfizer; Puma Biotechnology; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Carrick Pharm (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Innocrin Pharma (Inst); Novartis (Inst); Pfizer (Inst)
 
Mark E. Robson
Consulting or Advisory Role - Change HealthCare
Research Funding - AstraZeneca (Inst); Merck (Inst); Pfizer (Inst)
Other Relationship - Clinical Care Options; Invitae (Inst); Pfizer; Physicans' Education Resource; Research to Practice
(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo; Epic Sciences; Merck; Pfizer
 
Chau T. Dang
Honoraria - eviCore healthcare; Puma Biotechnology
Consulting or Advisory Role - eviCore healthcare; Puma Biotechnology
Research Funding - Genentech/Roche (Inst); Puma Biotechnology (Inst)